Statins in unconventional secretion of insulin-degrading enzyme and degradation of the amyloid-β peptide

Neurodegenerative Diseases

Volumn 10, Issue 1-4, 2012, Pages 309-312

  Glebov, Konstantin ^a   Walter, Jochen ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Alzheimer's disease; Insulin degrading enzyme; Metalloproteinase; SlyX motif; Statins; Unconventional secretion

Indexed keywords

AMYLOID BETA PROTEIN; CHOLESTEROL; HEXAPEPTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULINASE; ISOPRENOID;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ARTICLE; BIOSYNTHESIS; CARBOXY TERMINAL SEQUENCE; CONCENTRATION (PARAMETERS); DRUG EFFECT; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME RELEASE; EXOSOME; HUMAN; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION;

AMYLOID BETA-PEPTIDES; ANIMALS; EXOSOMES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULYSIN; MICROGLIA;

EID: 84860215655     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000332595     Document Type: Article

References (24)

1. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.
2. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM: Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009;80:13-17.
3. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy- 3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-1443.
4. Hartmann T: Cholesterol, A beta and Alzheimer's disease. Trends Neurosci 2001; 24:S45-S48.
5. Glenner GG, Wong CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-890.
6. Liao L, Cheng D, Wang J, Duong DM, Losik TG, Gearing M, Rees HD, Lah JJ, Levey AI, Peng J: Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem 2004; 279:37061-37068.
7. Abad-Rodriguez J, Ledesma MD, Craessaerts K, et al: Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 2004; 167: 953-960.
8. Cheng H, Vetrivel KS, Gong P, Meckler X, Parent A, Thinakaran G: Mechanisms of disease: new therapeutic strategies for Alzheimer's disease - Targeting APP processing in lipid rafts. Nat Clin Pract Neurol 2007; 3: 374-382.
9. Ehehalt R, Keller P, Haass C, Thiele C, Simons K: Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 2003; 160: 113-123.
10. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci USA 2001; 98: 5815-5820.
11. Longenberger J, Shah ZA: Simvastatin and other HMG-CoA reductase inhibitors on brain cholesterol levels in Alzheimer's disease. Curr Alzheimer Res 2011; 8: 434-442.
12. Miida T, Hirayama S, Nakamura Y: Cholesterol- independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb 2004; 11: 253-264.
13. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719.
14. Tamboli IY, Barth E, Christian L, et al: Statins promote the degradation of extracellular amyloid-3β peptide by microglia via stimulation of exosome-associated IDE secretion. J Biol Chem 2010; 285: 37405-37414.
15. Bulloj A, Leal MC, Xu H, Castano EM, Morelli L: Insulin-degrading enzyme sorting in exosomes: a secretory pathway for a key brain amyloid-beta degrading protease. J Alzheimers Dis 2010;19:79-95.
16. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ: Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998;273:32730-32738.
17. Zhao J, Li L, Leissring MA: Insulin-degrading enzyme is exported via an unconventional protein secretion pathway. Mol Neurodegener 2009;4:4.
18. Glebov K, Schutze S, Walter J: Functional relevance of a novel SlyX motif in non-conventional secretion of insulin-degrading enzyme. J Biol Chem 2011; 286: 22711-22715.
19. Keller S, Ridinger J, Rupp AK, Janssen JW, Altevogt P: Body fluid derived exosomes as a novel template for clinical diagnostics. J Transl Med 2011; 9: 86.
20. Simons M, Raposo G: Exosomes - Vesicular carriers for intercellular communication. Curr Opin Cell Biol 2009; 21: 575-581.
21. Admyre C, Telemo E, Almqvist N, et al: Exosomes - Nanovesicles with possible roles in allergic inflammation. Allergy 2008; 63: 404-408.
22. Taverna S, Flugy A, Saieva L, et al: Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis. Int J Cancer 2011, DOI: 10.1002/IJC.26217.
23. Hsu C, Morohashi Y, Yoshimura S, et al: Regulation of exosome secretion by Rab35 and its GTPase-activating proteins TBC1D10AC. J Cell Biol 2010; 189: 223-232.
24. Leung KF, Baron R, Seabra MC: Thematic review series: lipid posttranslational modifications. Geranylgeranylation of Rab GTPases. J Lipid Res 2006; 47: 467-475.